Antimelanoma immunity in vitiligo and melanoma patients

Neoplasma

Volumn 50, Issue 4, 2003, Pages 305-309

  Juranic Z D ^a   Stanojevic Bakic N ^a   Zizak Z ^a   Babovic N ^a   Radovic Kovacevic V ^b   Stanojkovic T ^a   Dzodic R ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b Clinic for Dermatovenerology   (Serbia)

Author keywords

Fem x; Melanoma Antimelanoma Immunity; MTT; Vitiligo

Indexed keywords

ADULT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE FUNCTION TEST; IMMUNOTOXICITY; MALE; MELANOMA; MONONUCLEAR CELL; TUMOR CELL; VITILIGO;

EID: 0141761471     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. AMEEN M, EXARCHOU V, CHU AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001; 145: 476-479.
2. CURRY BJ, MYERS K, HERSEY P. Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma. Recent Results Cancer Res 2001; 158: 211-230.
3. DURHAM-PIERRE DG, WALTERS CS, HALDER RM, PHAM HN, VANDERPOOL EA. Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995; 33: 26-30.
4. FISHMAN P, AZIZI E, SHOENFELD Y, SREDNI B, YECHESKEL G, FERRONE S, ZIGELMAN R, CHAITCHIK S, FLORO S, DJALDETTI M. Vitiligo autoantibodies are effective against melanoma. Cancer 1993; 72: 2365-2369.
5. FISHMAN P, MERIMSKY O, BAHARAV E, SHOENFELD Y. Antibodies to tyrosinase, the bridge between melanoma and vitiligo. Cancer 1997; 79: 14461-14464.
6. HANN SK, KIM JB. Detection of antibodies to melanoma cells in vitiligo by western immunoblotting. Yonsei Med J 1995; 36: 457-461.
7. HANN SK, KOO SW, KIM JB, PARK YK. Detection of antibodies to melanoma cells in vitiligo and alopecia areata by Western blot analysis. J Dermatol 1996; 23: 100-103.
8. HARNING R, CUI J, BYSTRYN JC. Relation between incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-1080.
9. 35S-labeled recombinant human tyrosinase in a radioimmunnoassay. J Invest Dermatol 1997; 109: 169-173.
10. MAILLIARD RB, LOTZE MT. Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets. Clin Cancer Res 2001; 7 Suppl: 980s-988s.
11. MERIMSKY O, SHOENFELD Y, CHAITCHIK S, YECHESKEL G, FISHMAN P. Antigens and antibodies in malignant melanoma. Tumour Biol 1994; 15: 188-202.
12. MERIMSKY O, SHOENFELD Y, YECHESKEL G, CHATCHIK S, AZIZI E, FISHMAN P. Vitiligo-and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 1994; 38: 411-416.
13. NAFTZGER C, TACECHI Y, KOHDA H, HARA I, VIAYASARADHI S, HOUGHTON AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 1996; 93: 14809-14814.
14. NORDLUND JJ, KIRKWOOD JM, FORGET BM, MILTON G, ALBERT DM, LERNER AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9: 689-696.
15. NORIS DA, KISSINGER RM, NAUGHTON GK, BYSTRIN JC. Evidence for immunologic mechanisms in human vitiligo: patients sera induced damage to human melanocyte in vitro by complement mediated damage and antibody-dependent cellular toxicity. J Invest Dermatol 1988; 90: 783-789.
16. OHNO M, ABE T. Rapid colorimetric assays for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J Immunol Methods 1991; 145: 199-203.
17. OKAMOTO T, IRIE RF, FUI S, HUANG SK, NICE AJ, MORTON DL, HOON DS. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific imunotherapy. J Invest Dermatol 1998; 111: 1034-1039.
18. ROCHA IM, OLIVEIRA LJN, CASTRO LCM, PEREIRA LIA, CHAUL A, GUERRA JG, SILVESTRE MC, BATISTA KM, PEREIRA FA, GOMIDE MAC, GUILLO LA. Recognition of melanoma cell antigens with antibodies present in sera from patients with vitiligo. Int J Dermatol 2000; 39: 840-843.
19. ROSENBERG SA, WHITE DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19: 81-84.
20. VAN DEN WIJNGAARD R, WANKOWICS-KALINSKA A, LE POOLE C, TIGGES B, WESTERHOF W, DAS P. Local immune response in skin of generalized vitiligo patients. Lab Invest 2000; 80: 1299-1309.
21. XIE Z, CHEN D,JIAO D, BYSTRIN JC. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol 1999; 135: 417-422.
22. YEE C, THOMPSON JA, ROCHE P, BYRD DR, LEE PP, PIEPKORN M, KENYON K, DAVIS MM, RIDDELL SR, GREENBERG PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192: 1637-1644.
23. YU HS, KAO CH, YU CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies. J Invest Dermatol 1993; 100: 823-828.